Working… Menu
Trial record 7 of 32 for:    Hydrogen Sulfide

Hydrogen Sulfide as Prognostic Factor (H2S-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01088490
Recruitment Status : Completed
First Posted : March 17, 2010
Last Update Posted : December 5, 2014
Information provided by (Responsible Party):
Podbregar Matej, University Medical Centre Ljubljana

Brief Summary:
Hydrogen sulfide (H2S), better known as a poisonous gas, has emerged as the third gaseous transmitter in mammals, next to nitric oxide (NO) and carbon monoxide (CO). Increased production and higher serum concentrations were shown in inflammatory diseases, septic shock and stroke. The investigators will test the hypothesis that higher serum H2S concentrations on admission to intensive care unit (ICU) are linked with higher mortality in patients with shock of any reason.

Condition or disease
Mortality Shock

  Show Detailed Description

Layout table for study information
Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hydrogen Sulfide as Prognostic Factor
Study Start Date : January 2010
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2014

critically ill
Critically ill patients admitted to ICU

Primary Outcome Measures :
  1. Prognostic value of H2S [ Time Frame: In hospital; ICU mortality 30days ]

    relationship between H2S and mortality of patients during intensive care treatment,

    comparison of H2S and lactate prognostic value

Secondary Outcome Measures :
  1. Correlation of H2S with vasopressor requirements [ Time Frame: ICU treatmennt 30days ]
    relationship between H2S and dose of vasopressors (noradrenaline, epinephrine) used

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Critically ill patients how are admitted in shock or hemodynamicaly unstable ino intensive care

Inclusion Criteria:

  • shock ( systemic arterial pressure less then 120mmHg, elevated lactate > 2.5mmol/L)

Exclusion Criteria:

  • patients admitted due to intoxication with H2S

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01088490

Layout table for location information
University Medical Center
Ljubljana, Slovenia, 1000
Sponsors and Collaborators
University Medical Centre Ljubljana
Layout table for investigator information
Principal Investigator: Matej Podbregar, MD PhD University Medical Centre Ljubljana

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Podbregar Matej, Prof., University Medical Centre Ljubljana Identifier: NCT01088490     History of Changes
Other Study ID Numbers: H2S_1
First Posted: March 17, 2010    Key Record Dates
Last Update Posted: December 5, 2014
Last Verified: December 2014
Keywords provided by Podbregar Matej, University Medical Centre Ljubljana:
Hydrogen sulfide
critically ill
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrogen Sulfide
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs